文摘
摘要目的:获得患者神经影像学在COVID-19使用低场,便携式核磁共振成像(MRI)设备。
背景:神经成像的一个关键步骤是脑损伤的临床评价。常规MRI系统运行在高强度磁场(1.5 3 t)要求病人交通访问权限控制的已命名的环境。COVID-19大流行期间,危重病人神经影像有限由于感染控制和安全问题。我们报告严重患者的神经影像COVID-19使用便携式核磁共振成像装置。
设计/方法:64吨医疗点(POC) MRI用于获取神经影像学在耶鲁大学纽黑文医院icu从2020年4月到2020年8月。COVID-19患者神经系统症状和没有扫描MRI禁忌症。考试是使用一个标准的110伏/ 15电源插座。医院房间包括生命体征监测、通风、透析机器,和静脉输液泵。训练有素的研究人员获得的图像,而不需要核磁共振技术员。POC MRI考试被解读为两个执照医生(一个neuroradiologist和一个神经学家)。
结果:POC MRI考试获得22日ICU COVID-19病人(19%为女性,年龄在42 - 74年,86%的机械通风)。格拉斯哥昏迷评分和里士满Agitation-Sedation规模时扫描7±3−3±2,分别。t1 (T1W), t2加权(T2W) fluid-attenuated反转恢复(天赋),和diffusion-weighted成像(驾车)序列所有患者均获得。轴向扫描时间4:54分钟,7:03分钟,31分钟,分别9:04分。考试时间是35:40分钟。异常的神经影像学研究结果中观察到10位病人:颅内出血(n = 2),脑梗死(n = 4),弥漫性脑水肿(n = 1),和脑白质病(n = 3)。设备不会影响到加护病房设备,并没有明显的不良事件发生。
结论:我们报告的使用低场神经影像,床边的便携式核磁共振COVID-19患者严重。这种方法可能持有承诺床边评估神经损伤与成像设置访问限制。
披露:Mazurek小姐没有披露。袁先生没有披露。卡恩先生没有披露。马修·罗森获得股票或超精细研究的所有者权益。马修·罗森获得股票或BlinkAI的所有者权益。马修·罗森获得股票或一个所有权Vizma生命科学的兴趣。马修·罗森获得股票或完整的数据服务的所有权。马修·罗森的机构收到通用电气医疗集团的研究支持。马修·罗森已收到知识产权利益从发现或技术有关卫生保健。Gobeske博士没有披露。 Dr. Gilmore has nothing to disclose. Dr. Hwang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Portola Pharmaceuticals. The institution of Dr. Hwang has received research support from Apple Pickers Foundation. The institution of an immediate family member of Dr. Hwang has received research support from National Institute of Health. The institution of an immediate family member of Dr. Hwang has received research support from American Diabetes Association. The institution of an immediate family member of Dr. Hwang has received research support from General Electric. Dr. Hwang has received publishing royalties from a publication relating to health care. Dr. Hwang has received personal compensation in the range of $5,000-$9,999 for serving as a Principal Investigator with Society of Critical Care Medicine. Dr. Hwang has a non-compensated relationship as a Board of Directors with Neurocritical Care Society that is relevant to AAN interests or activities. Dr. Kaddouh has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Falcone has nothing to disclose. Dr. Petersen has received research support from NIH. The institution of Jonathan Siner has received research support from NHLBI. The institution of Dr. Spudich has received research support from NIH. Gordon Sze has nothing to disclose. Dr. Kimberly has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for NControl Therapeutics. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Kimberly has received research support from Biogen. The institution of Dr. Kimberly has received research support from NControl Therapeutics. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
